The stock of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is a huge mover today! The stock decreased 2.48% or $0.38 during the last trading session, reaching $14.97. About 657,305 shares traded. Adverum Biotechnologies, Inc. (NASDAQ:ADVM) has risen 7.50% since July 12, 2018 and is uptrending. It has outperformed by 3.07% the S&P500.
The move comes after 7 months negative chart setup for the $936.50 million company. It was reported on Jul, 12 by Barchart.com. We have $14.52 PT which if reached, will make NASDAQ:ADVM worth $28.09 million less.
Analysts await Adverum Biotechnologies, Inc. (NASDAQ:ADVM) to report earnings on August, 14. They expect $-0.30 EPS, 0.00 % or $0.00 from last year’s $-0.3 per share. After $-0.23 actual EPS reported by Adverum Biotechnologies, Inc. for the previous quarter, Wall Street now forecasts 30.43 % negative EPS growth.
More notable recent Adverum Biotechnologies, Inc. (NASDAQ:ADVM) news were published by: Globenewswire.com which released: “Report: Developing Opportunities within Adverum Biotechnologies, Aurinia Pharmaceuticals, Baytex Energy, Limelight Networks, Park City Group, and HealthStream â€” Future Expectations, Projections Moving into 2019 – GlobeNewswire” on April 08, 2019, also Benzinga.com with their article: “The Daily Biotech Pulse: Inovio’s Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation – Benzinga” published on May 29, 2019, Globenewswire.com published: “Adverum Biotechnologies Doses First Patient in Second Cohort of OPTIC Phase 1 Clinical Trial of ADVM-022 Gene Therapy for Wet AMD – GlobeNewswire” on June 10, 2019. More interesting news about Adverum Biotechnologies, Inc. (NASDAQ:ADVM) were released by: Globenewswire.com and their article: “Adverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022 Gene Therapy in Wet Age-Related Macular Degeneration – GlobeNewswire” published on November 19, 2018 as well as Globenewswire.com‘s news article titled: “Adverum Biotechnologies Announces Long-term Preclinical Efficacy Data on ADVM-022 Gene Therapy in Wet AMD – GlobeNewswire” with publication date: May 01, 2018.
Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has market cap of $936.50 million. The firm has a pipeline that includes product candidates to treat wet age-related macular degeneration , alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. It currently has negative earnings. The Company’s lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.